Contact Us | Language: čeština English
Title: | Karcinom prsu u mužů | ||||||||||
Author: | Gatěk, Jiří; Duben, Jiří; Dudešek, Bohumil; Ratajský, Martin; Holík, Pavel; Zábojníková, Michaela; Vrána, David | ||||||||||
Document type: | Peer-reviewed article (Czech) | ||||||||||
Source document: | Onkologie (Czech Republic). 2020, vol. 14, issue Suppl. E, p. 106-111 | ||||||||||
ISSN: | 1802-4475 (Sherpa/RoMEO, JCR) | ||||||||||
Journal Impact
This chart shows the development of journal-level impact metrics in time
|
|||||||||||
DOI: | https://doi.org/10.36290/xon.2020.066 | ||||||||||
Abstract: | Male breast cancer is rare disease and it represents 1 % breast cancer. Invasive ductal cancer dominates in histology with 10 % portion in situ carcinoma. Other histology types are extraordinary. Female breast carcinoma has different diversion in molecular subtype than male carcinoma, which is predominant hormonal sensitive. Mastectomy is procedure of choice with sentinel node biopsy or axillary dissection in surgery. Radiotherapy is used after breast conservative procedure. Indication after mastectomy depends on stage of the carcinoma. Hormonal therapy is mainly applied in adjuvant therapy and mostly with Tamoxifen. Male carcinoma is very similar with female carcinoma but is not identical. Medical care come out from experience with treatment female carcinoma. Contemporary knowledge about male carcinoma needs new trials oriented on male carcinoma. © 2020 SOLEN s.r.o.. All rights reserved. | ||||||||||
Full text: | www.onkologiecs.cz/artkey/xon-202092-0002_karcinom_prsu_u_muzu.php | ||||||||||
Show full item record |